Skip to main content
    R

    Royalty Pharma Plc (RPRX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $68.53
    -0.79 (-1.13%)

    Market Cap: $39.85B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Royalty Pharma Plc (RPRX) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Royalty Pharma Plc are Roivant Sciences (ROIV), BridgeBio Pharma (BBIO) and Revolution Medicines (RVMD). Royalty Pharma Plc trades at 12.9x earnings, against a median of 30.0x for the 7 of these companies with a P/E. By market cap, Royalty Pharma Plc ranks 5th of the 13 companies on this page; Vertex Pharmaceuticals (VRTX) is the largest at $136.56B.

    Peer Comparison

    RPRX's ROIC of 7.6% is above the peer median of 4.8%, and its revenue growth of 13.3% is below the median of 35.0%. It yields 1.37%, while the median peer pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Royalty Pharma Plc (RPRX)$39.85B12.9x11.7x25.7%7.6%13.3%1.37%
    Roivant Sciences Ltd (ROIV)$28.64BN/A679.3x0.0%N/A2136.0%0.00%
    BridgeBio Pharma Inc (BBIO)$15.25BN/A16.0x-59.8%-33.0%192.6%0.00%
    Revolution Medicines Inc (RVMD)$37.27BN/A181.6x0.0%-52.1%-95.2%0.00%
    BeOne Medicines AG (ONC)$47.58B50.0x18.7x13.9%7.5%33.8%0.00%
    Jazz Pharmaceuticals PLC (JAZZ)$15.50B18.4x3.3x4.4%3.5%10.4%0.00%
    Regeneron Pharmaceuticals Inc (REGN)$98.84B18.4x5.7x28.5%13.7%36.3%0.39%
    Insmed Inc (INSM)$26.58BN/A17.7x-39.9%-44.2%268.4%0.00%
    Vertex Pharmaceuticals Inc (VRTX)$136.56B30.0x10.5x30.7%14.2%11.8%0.00%
    argenx NV ADR (ARGX)$60.37B33.5x6.1x31.7%N/A52.1%0.00%
    Genmab AS (GMAB)$31.67B35.8x19.2x17.0%4.8%16.1%0.00%
    Ascendis Pharma AS (ASND)$18.06BN/A13.5x72.9%12.4%73.0%0.00%
    Exelixis Inc (EXEL)$16.84B19.3x6.9x35.4%N/A10.2%0.00%
    Peer median$30.16B30.0x14.7x15.4%4.8%35.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Royalty Pharma Plc, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Roivant Sciences Ltd (ROIV)
    Roivant Sciences Ltd (ROIV) is a transformative biopharmaceutical company focused on advancing drug development and commercialization through a distinctive...
    ROIV competitors
    BridgeBio Pharma Inc (BBIO)
    BridgeBio Pharma, Inc. is dedicated to the discovery, development and supply of various drugs for genetic diseases.
    BBIO competitors
    Revolution Medicines Inc (RVMD)
    Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted...
    RVMD competitors
    BeOne Medicines AG (ONC)
    BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe...
    ONC competitors
    Jazz Pharmaceuticals PLC (JAZZ)
    Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and markets pharmaceutical products for various unmet medical needs in the United...
    JAZZ competitors
    Regeneron Pharmaceuticals Inc (REGN)
    Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York.
    REGN competitors
    Insmed Inc (INSM)
    Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases.
    INSM competitors
    Vertex Pharmaceuticals Inc (VRTX)
    Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
    VRTX competitors
    argenx NV ADR (ARGX)
    argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases...
    ARGX competitors
    Genmab AS (GMAB)
    Genmab A / S develops antibody therapies for the treatment of cancer and other diseases mainly in Denmark. The company is headquartered in Copenhagen, Denmark.
    GMAB competitors
    Ascendis Pharma AS (ASND)
    Ascendis Pharma A / S, a biopharmaceutical company, develops therapies for unmet medical needs. The company is headquartered in Hellerup, Denmark.
    ASND competitors
    Exelixis Inc (EXEL)
    Exelixis, Inc., an oncology-focused biotechnology company, is focused on the discovery, development...
    EXEL competitors

    Frequently Asked Questions About RPRX

    Who are Royalty Pharma Plc's main competitors?

    The companies most similar to Royalty Pharma Plc include Roivant Sciences (ROIV), BridgeBio Pharma (BBIO), Revolution Medicines (RVMD), BeOne Medicines AG (ONC) and Jazz Pharmaceuticals (JAZZ), listed from the closest match.

    Who is Royalty Pharma Plc's biggest competitor?

    Vertex Pharmaceuticals (VRTX) is the largest of the similar companies at $136.56B; Roivant Sciences (ROIV) is the closest match by business profile, size, sector and industry.

    How does RPRX stock compare with its competitors?

    RPRX's P/E is 12.9x against a peer median of 30.0x; its P/S is 11.7x against a peer median of 14.7x; its net margin is 25.7% against a peer median of 15.4%.

    Which of Royalty Pharma Plc's competitors pays a higher dividend?

    Royalty Pharma Plc has a forward dividend yield of 1.37%. None of the similar companies with available yields has a higher forward dividend yield.

    Is Royalty Pharma Plc bigger than its competitors?

    No. Royalty Pharma Plc is 5th by market cap among the 13 companies on this page; the largest is Vertex Pharmaceuticals (VRTX) at $136.56B.